OMERS ADMINISTRATION Corp Cuts Stock Holdings in Abbott Laboratories $ABT

OMERS ADMINISTRATION Corp lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 93.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,874 shares of the healthcare product maker’s stock after selling 941,775 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Abbott Laboratories were worth $8,880,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Sienna Gestion acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth $917,000. Tobias Financial Advisors Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter worth $298,000. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its position in shares of Abbott Laboratories by 1.7% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 7,855 shares of the healthcare product maker’s stock worth $984,000 after acquiring an additional 135 shares in the last quarter. USS Investment Management Ltd increased its position in shares of Abbott Laboratories by 0.7% in the fourth quarter. USS Investment Management Ltd now owns 290,576 shares of the healthcare product maker’s stock worth $36,402,000 after acquiring an additional 2,151 shares in the last quarter. Finally, WealthTrust Axiom LLC increased its position in shares of Abbott Laboratories by 3.2% in the fourth quarter. WealthTrust Axiom LLC now owns 3,064 shares of the healthcare product maker’s stock worth $384,000 after acquiring an additional 94 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 0.7%

NYSE ABT opened at $88.76 on Tuesday. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The company has a market capitalization of $154.60 billion, a price-to-earnings ratio of 24.86, a price-to-earnings-growth ratio of 1.47 and a beta of 0.63. The company’s fifty day moving average price is $91.17 and its two-hundred day moving average price is $107.56.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the prior year, the firm posted $1.09 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is 70.59%.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on ABT shares. Citigroup dropped their price objective on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, April 17th. BTIG Research reissued a “buy” rating and issued a $131.00 price objective on shares of Abbott Laboratories in a research report on Monday, April 27th. Piper Sandler dropped their price objective on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. TD Cowen lowered their price target on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.38.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.